MedTrace Logo

Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients

NCT01496339 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-06-07

No results posted yet for this study

Summary

The purpose of this study is to investigate whether the treatment of human menstrual blood-derived mesenchymal stem cells which would be applied to diabetes patients is safe and effective.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

BIOLOGICAL

MenSCs transplantation

1×10\^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.

DRUG

exogenous indulin injection daily

traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.

Sponsors & Collaborators

  • Zhejiang University

    collaborator OTHER

  • Wenzhou Medical University

    collaborator OTHER

  • Zhenjiang First People's Hospital

    collaborator OTHER

  • S-Evans Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Charile Xiang, Professor · S-Evans Biosicences Co.,Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01496339 on ClinicalTrials.gov